COVID-19 vaccine developed by Oxford shows promising results, Phase 3 trials underway

In what might be a major breakthrough in battle against vel Coronavirus, Oxford scientists have stated that early trials of potential vaccine have shown promising results. potential vaccine named - ChOx1 nCoV-19 vaccine - has been developed by Oxford in partnership with English drugmakers AstraZeneca. In a preliminary report published in table Lancet Journal, scientists have stated that during randomised trials, individuals which received a shot of ChOx1 nCoV-19 vaccine showed ' verse effects' and a single dose elicits an increase in spike-specific antibodies by day 28. 

"ChOx1 nCoV-19 was safe, tolerated, and immugenic, while reactogenicity was reduced with paracetamol. A single dose elicited both humoral and cellular responses against SARS-CoV-2, with a booster immunisation augmenting neutralising antibody titres. preliminary results of this first-in-human clinical trial supported clinical development progression into ongoing phase 2 and 3 trials," study published in Lancet re. 

RE | UK Signs Deals To Secure ditional 90 Million Doses Of Potential Coronavirus Vaccines

'Phase 3 trials underway'

However, it also highlighted that small number of participants might be a limitation for student. Neverless, it informed that developers are w recruiting older groups with comorbidities, health-care workers, and those with a higher risk for SARS-CoV-2 exposure to furr assess potential vaccine. "We will also evaluate vaccine in children, once sufficient safety data have been accumulated in ult studies. Phase 3 trials are w underway in Brazil, South Africa, and UK and will evaluate vaccine efficacy in diverse populations," study concluded.

RE | Team Led By JNU Prof Develops Vaccine Candidate Against Streptococcus

Responding to results shown, Dr rian Hill, director of Jenner Institute at Oxford University while speaking to AP stated that vaccine triggers 'both arms of immune system.' He also informed that immune response might be boosted after a second dose of vaccine and cautioned that even 2 billion doses may t be eugh to battle pandemic. Numerous countries including Germany, France, Nerlands, Italy, U.S. and U.K. have all signed deals to receive hundreds of millions of doses of vaccine, which has t yet been licensed.

RE | UK Prime-minister On Schools, Virus Vaccine, China

RE | rth Goa Hospital Prepares For COVID-19 Vaccine Trials